Mpox (Monkeypox)
13
3
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (13)
Investigating MPXV Viral Clearance in Mpox Cases and Secondary Attack Rate in Contacts
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : Guinea
Ocular Complications of Mpox in the Democratic Republic Congo
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)
Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only
An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC
Epidemiological and Clinical Characteristics of Mpox Outbreak in Equateur, the DR Congo (Part1)
Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)
DiagRaMIE Mpox Virus-RDC for the Diagnostic of Monkeypox
Mpox Biology, Outcome, Transmission and Epidemiology
Looking for Asymptomatic Mpox in a Population at High Risk